Wells Fargo analyst Cerena Chen added Axsome Therapeutics to the firm’s Q4 2024 Tactical Ideas List. The catalyst path looks attractive in Q4 2024 as Wells thinks AXS-05 odds of approval for AD agitation are underappreciated and thus sees a favorable setup going into readout. Positive ADHD data could unlock further value, the firm adds. Wells has an Overweight rating on the shares with a price target of $140.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Biotech Alert: Searches spiking for these stocks today
- Axsome Therapeutics announces FDA acceptance of NDA resubmission for AXS-07
- Axsome Therapeutics initiated with an Overweight at Wells Fargo
- Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
- Axsome Therapeutics price target lowered to $130 from $131 at RBC Capital